TherapeuticsMD & Mayne Pharma v. Sun Pharma: IMVEXXY® Patent Case Consolidated
TherapeuticsMD and Mayne Pharma asserted 20 Orange Book-listed patents against Sun Pharmaceutical’s generic estradiol vaginal insert ANDA in the District of New Jersey. After 439 days, Case No. 2:24-cv-07974 was consolidated with a related 2020 action, concentrating all IMVEXXY® patent disputes into a single trial track.
A 20-Patent ANDA Battle Over IMVEXXY® Enters Unified Trial Track
TherapeuticsMD, Inc. and Mayne Pharma LLC filed Case No. 2:24-cv-07974 on July 24, 2024 in the District of New Jersey against Sun Pharmaceutical Industries, Inc., alleging infringement of 20 Orange Book-listed patents protecting IMVEXXY® (estradiol vaginal inserts, 4 mcg and 10 mcg). The asserted patents span formulation, dosing, and method-of-use claims tied to Sun’s ANDA for generic estradiol vaginal inserts at 0.004 mg and 0.01 mg strengths.
On October 3, 2025, the court issued a consolidation order merging 2:24-cv-07974 with the earlier-filed Civil Action No. 2:20-cv-03485, which involved the same plaintiffs, the same IMVEXXY® Orange Book patents, and both Sun Pharmaceutical and Teva Pharmaceuticals USA as defendants. Consolidation was ordered for the purposes of discovery, case management, and trial, effectively closing the 2024 docket as a standalone proceeding.
The consolidation reflects a common judicial efficiency strategy in multi-defendant ANDA litigation: rather than running parallel proceedings on identical patent portfolios and the same reference listed drug, the court unified the cases into a single trial track. Notably, the parties agreed to consolidation but retained a disputed issue regarding the fact-discovery deadline, which the court resolved in the same order. The merged proceeding will ultimately determine whether Sun’s generic can lawfully enter the estradiol vaginal insert market.
Filing to Case Consolidated in 439 days
439 days from filing to consolidation order — consistent with ANDA litigation timelines in NJ
Cases merged: what consolidation means for the IMVEXXY® litigation
Consolidation closes 2024 docket — litigation continues in unified action
A consolidation order under Federal Rule of Civil Procedure 42(a) merges related actions sharing common questions of law or fact. Here, both cases involved the same plaintiffs, the same IMVEXXY® Orange Book patents, and generic ANDA defendants. The 2024 case is administratively closed as a standalone docket; all claims, patents, and parties are absorbed into the consolidated action under Case No. 20-3485. No merits ruling has been issued.
No merits adjudicationPlaintiffs gain efficiency — all 20 patents litigated in one coordinated proceeding
Consolidation is typically neutral-to-favourable for patent holders asserting the same portfolio against multiple ANDA filers. TherapeuticsMD and Mayne Pharma can now coordinate discovery across Sun and Teva in a single forum, reducing duplicative expert reports and claim construction proceedings. The full 20-patent Orange Book portfolio remains live and unadjudicated, preserving injunctive relief and damages claims through trial.
Portfolio intact — trial pendingSun Pharma faces consolidated exposure alongside Teva in one trial
Consolidation places Sun Pharmaceutical alongside Teva Pharmaceuticals as co-defendants in a single proceeding, which may increase litigation costs and coordination complexity. Sun’s ANDA for estradiol vaginal inserts remains blocked during the Hatch-Waxman 30-month stay period, and no carve-out or early resolution has been recorded in the public docket. The merged schedule — including the disputed fact-discovery deadline — will govern Sun’s path to trial.
Market entry remains blockedUnified ANDA trial sharpens risk calculus for the generic estradiol market
With 20 Orange Book patents covering IMVEXXY® now defended in a single consolidated action against two major generic filers, the litigation creates a high-stakes barrier to the generic estradiol vaginal insert market. Pharmaceutical companies evaluating entry into this space should monitor the consolidated trial schedule closely. A plaintiff win across even a subset of the 20 patents could extend market exclusivity significantly; a defendant win on all could open a competitive generic market simultaneously for both Sun and Teva.
Market entry contingent on trial outcomeFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Therapeuticsmd, Inc. | Company | Pharmaceutical IP holders — co-owners of 20 Orange Book patents for IMVEXXY® estradiol vaginal insertsSearch in Eureka ↗ |
| Co-Plaintiff | Mayne Pharma, LLC | Company | Search in Eureka ↗ |
| Defendant | Sun Pharmaceutical Industries, Inc. | Company | Sun Pharmaceutical Industries, Inc. — generic pharmaceutical company seeking ANDA approval for estradiol vaginal insertsSearch in Eureka ↗ |
| Co-Defendant | Sun Pharmaceutical Industries, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Alexander Lee Callo | Attorney | Counsel for Therapeuticsmd, Inc.Search in Eureka ↗ |
| Plaintiff counsel | William C. Baton | Attorney | Counsel for Therapeuticsmd, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Saul Ewing LLP | Law Firm | Representing Therapeuticsmd, Inc.Search in Eureka ↗ |
| Defendant counsel | CATHERINE SALERNO | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Defendant counsel | Gregory D. Miller | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Defendant counsel | Timothy P. Gonzalez | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Defendant law firm | Rivkin Radler LLP | Law Firm | Representing Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s October 2025 order is procedural rather than substantive: it consolidates two related ANDA patent actions for efficiency without adjudicating infringement, validity, or enforceability on the merits. The order resolves a discrete scheduling dispute — the fact-discovery deadline — while deferring all substantive patent questions to the unified proceeding. For practitioners, the consolidation signals that the court views the two dockets as materially identical in their legal and factual foundations, which may inform how claim construction and expert discovery are structured going forward.
US11065197B2 and 19 further patents — IMVEXXY® estradiol vaginal insert formulations
The 20 asserted patents cover a range of formulation, composition, and method-of-use claims related to IMVEXXY® — a low-dose estradiol vaginal insert indicated for moderate-to-severe dyspareunia due to vulvar and vaginal atrophy. The patents span application filings from 2013 (US9180091B2, filed US14/136048) through 2020, reflecting iterative innovation around estradiol delivery, excipient selection, dosing regimens, and insert geometry. All 20 are listed in the FDA’s Orange Book for IMVEXXY®, making them automatically enforceable against ANDAs referencing the product under the Hatch-Waxman framework.
The breadth of the portfolio — 20 patents covering overlapping aspects of the same reference listed drug — is consistent with a deliberate lifecycle management strategy common in specialty pharmaceutical development. For generic entrants, invalidating or designing around the full portfolio requires mounting distinct challenges across formulation, process, and method claims simultaneously. The portfolio’s concentration in a single Orange Book product also means that a successful IPR or district court invalidity ruling on core composition claims could cascade through the entire assertion strategy, making individual patent strength a critical variable for both sides.
Should you run an FTO analysis against the IMVEXXY® Orange Book patent portfolio?
Any company developing or commercialising estradiol vaginal insert products — including ANDA filers, 505(b)(2) applicants, or novel formulation developers — faces direct exposure to this 20-patent portfolio. The Orange Book listing means automatic 30-month stay risk upon ANDA submission. R&D teams evaluating ultra-low-dose estradiol delivery, vaginal insert excipient design, or mucoadhesive drug delivery systems should conduct a comprehensive FTO review before committing to development expenditure.
PatSnap Eureka’s FTO Search Agent can map each of the 20 asserted patents against your specific formulation parameters, claim scope, and product design in minutes. Eureka identifies prior art gaps, flags dependent versus independent claim risk, and benchmarks your exposure against the full Orange Book listing for IMVEXXY® — giving your IP and regulatory teams a consolidated risk picture ahead of ANDA filing or commercial launch.
Run a freedom-to-operate analysis on US11065197B2 to assess your product’s exposure
Run FTO in Eureka →Similar Orange Book ANDA patent cases in the District of New Jersey
Related Hatch-Waxman ANDA patent infringement cases involving Orange Book-listed pharmaceutical patents litigated in the District of New Jersey.
What this case signals for the women’s health pharmaceutical IP landscape
A 20-patent Orange Book assertion consolidated against two ANDA filers illustrates the layered enforcement strategies emerging in specialty pharmaceutical litigation.
Orange Book patent stacking remains a potent ANDA barrier in women’s health
TherapeuticsMD and Mayne Pharma asserted 20 Orange Book-listed patents — spanning formulation, dosing method, and use claims — against a single generic ANDA product. This layered approach maximises the 30-month stay period and forces challengers to invalidate or design around a large, heterogeneous patent portfolio before market entry.
Consolidation with a 2020 action signals long litigation runway for IMVEXXY®
The merger of a 2024 filing with a case commenced in 2020 suggests the IMVEXXY® patent dispute has already run more than five years without merits resolution. Companies tracking this space should anticipate further delay before any final determination on validity or infringement — and plan generic entry timelines accordingly.
Therapeuticsmd v Sun — key questions answered
Case 2:24-cv-07974 was consolidated with Case No. 2:20-cv-03485 by court order on October 3, 2025. The 2024 case, filed by TherapeuticsMD and Mayne Pharma against Sun Pharmaceutical alleging infringement of 20 Orange Book patents for IMVEXXY®, was merged for discovery and trial with the earlier related action. No merits ruling on infringement or validity was issued.
Twenty Orange Book-listed patents are asserted, including US11065197B2, US11304959B2, US10398708B2, US10537581B2, US10471072B2, US10568891B2, US10806697B2, US11246875B2, US9180091B2, US10668082B2, US11351182B2, US11497709B2, US11266661B2, US10258630B2, US11241445B2, US10835487B2, US11123283B2, US10888516B2, US9289382B2, and US11116717B2 — all covering aspects of estradiol vaginal insert formulations and methods of use.
Consolidation under FRCP 42(a) merges cases sharing common legal and factual questions into a single proceeding. In ANDA litigation, courts frequently consolidate actions involving the same reference listed drug and patent portfolio against different generic filers. The consolidated case proceeds under one docket for discovery and trial, reducing duplication while preserving each defendant’s separate legal posture on invalidity and non-infringement.
The public record does not disclose any resolution of the 30-month Hatch-Waxman stay or any consent judgment permitting launch. Sun’s ANDA for estradiol vaginal inserts at 0.004 mg and 0.01 mg remains subject to active litigation in the consolidated proceeding, which suggests market entry remains blocked pending trial outcome or a negotiated settlement.
TherapeuticsMD and Mayne Pharma are represented by Saul Ewing LLP, with attorneys Alexander Lee Callo and William C. Baton on record. Sun Pharmaceutical is represented by Rivkin Radler LLP, with Catherine Salerno, Gregory D. Miller, and Timothy P. Gonzalez appearing as counsel of record.
PatSnap Eureka searches patents and litigation data to answer instantly.